Fatal Human Rabies Infection With Suspected Host-Mediated Failure of Post-Exposure Prophylaxis Following a Recognized Zoonotic Exposure-Minnesota, 2021.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
13 Oct 2023
Historique:
received: 07 12 2022
medline: 27 11 2023
pubmed: 30 3 2023
entrez: 29 3 2023
Statut: ppublish

Résumé

No human rabies post-exposure prophylaxis (PEP) failure has been documented in the United States using modern cell culture-based vaccines. In January 2021, an 84-year-old male died from rabies 6 months after being bitten by a rabid bat despite receiving timely rabies PEP. We investigated the cause of breakthrough infection. We reviewed medical records, laboratory results, and autopsy findings and performed whole-genome sequencing (WGS) to compare patient and bat virus sequences. Storage, administration, and integrity of PEP biologics administered to the patient were assessed; samples from leftover rabies immunoglobulin were evaluated for potency. We conducted risk assessments for persons potentially exposed to the bat and for close patient contacts. Rabies virus antibodies present in serum and cerebrospinal fluid were nonneutralizing. Antemortem blood testing revealed that the patient had unrecognized monoclonal gammopathy of unknown significance. Autopsy findings showed rabies meningoencephalitis and metastatic prostatic adenocarcinoma. Rabies virus sequences from the patient and the offending bat were identical by WGS. No deviations were identified in potency, quality control, administration, or storage of administered PEP. Of 332 persons assessed for potential rabies exposure to the case patient, 3 (0.9%) warranted PEP. This is the first reported failure of rabies PEP in the Western Hemisphere using a cell culture-based vaccine. Host-mediated primary vaccine failure attributed to previously unrecognized impaired immunity is the most likely explanation for this breakthrough infection. Clinicians should consider measuring rabies neutralizing antibody titers after completion of PEP if there is any suspicion for immunocompromise.

Sections du résumé

BACKGROUND BACKGROUND
No human rabies post-exposure prophylaxis (PEP) failure has been documented in the United States using modern cell culture-based vaccines. In January 2021, an 84-year-old male died from rabies 6 months after being bitten by a rabid bat despite receiving timely rabies PEP. We investigated the cause of breakthrough infection.
METHODS METHODS
We reviewed medical records, laboratory results, and autopsy findings and performed whole-genome sequencing (WGS) to compare patient and bat virus sequences. Storage, administration, and integrity of PEP biologics administered to the patient were assessed; samples from leftover rabies immunoglobulin were evaluated for potency. We conducted risk assessments for persons potentially exposed to the bat and for close patient contacts.
RESULTS RESULTS
Rabies virus antibodies present in serum and cerebrospinal fluid were nonneutralizing. Antemortem blood testing revealed that the patient had unrecognized monoclonal gammopathy of unknown significance. Autopsy findings showed rabies meningoencephalitis and metastatic prostatic adenocarcinoma. Rabies virus sequences from the patient and the offending bat were identical by WGS. No deviations were identified in potency, quality control, administration, or storage of administered PEP. Of 332 persons assessed for potential rabies exposure to the case patient, 3 (0.9%) warranted PEP.
CONCLUSIONS CONCLUSIONS
This is the first reported failure of rabies PEP in the Western Hemisphere using a cell culture-based vaccine. Host-mediated primary vaccine failure attributed to previously unrecognized impaired immunity is the most likely explanation for this breakthrough infection. Clinicians should consider measuring rabies neutralizing antibody titers after completion of PEP if there is any suspicion for immunocompromise.

Identifiants

pubmed: 36988328
pii: 7093064
doi: 10.1093/cid/ciad098
doi:

Substances chimiques

Rabies Vaccines 0
Antibodies, Viral 0

Types de publication

Case Reports Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1201-1208

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.

Déclaration de conflit d'intérêts

Potential conflicts of interest. R. M. W. reports a role as a board member for the International Rabies Taskforce. R. L. reports roles on the ID Week Program Committee, the Council of State and Territorial Epidemiologists Executive Board, and the National Foundation for Infectious Diseases Executive Board and serving as an associate editor for AAP Red Book (Report of the Committee on Infectious Diseases) and declares support for attending meetings and/or travel from each; payment or honoraria received for their associate editor role was donated to the Minnesota Department of Health. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Auteurs

Stacy M Holzbauer (SM)

Minnesota Department of Health, St. Paul, Minnesota, USA.
Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Caroline A Schrodt (CA)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Rajesh M Prabhu (RM)

Essentia Health, Duluth, Minnesota, USA.

Rebecca J Asch-Kendrick (RJ)

Midwest Medical Examiner's Office, Ramsey, Minnesota, USA.

Malia Ireland (M)

Minnesota Department of Health, St. Paul, Minnesota, USA.

Carrie Klumb (C)

Minnesota Department of Health, St. Paul, Minnesota, USA.

Melanie J Firestone (MJ)

Minnesota Department of Health, St. Paul, Minnesota, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Gongping Liu (G)

Minnesota Department of Health, St. Paul, Minnesota, USA.

Katie Harry (K)

Minnesota Department of Health, St. Paul, Minnesota, USA.

Jana M Ritter (JM)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Min Z Levine (MZ)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lillian A Orciari (LA)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Kimberly Wilkins (K)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Pamela Yager (P)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Crystal M Gigante (CM)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

James A Ellison (JA)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Hui Zhao (H)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michael Niezgoda (M)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Yu Li (Y)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Robin Levis (R)

US Food and Drug Administration, Silver Spring, Maryland, USA.

Dorothy Scott (D)

US Food and Drug Administration, Silver Spring, Maryland, USA.

Panayampalli S Satheshkumar (PS)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Brett W Petersen (BW)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Agam K Rao (AK)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

W Robert Bell (WR)

University of Minnesota, Minneapolis, Minnesota, USA.

Sonja M Bjerk (SM)

Essentia Health, Duluth, Minnesota, USA.

Sara Forrest (S)

Essentia Health, Duluth, Minnesota, USA.

Wangcai Gao (W)

Allina Health, Minneapolis, Minnesota, USA.

Richard Dasheiff (R)

Essentia Health, Duluth, Minnesota, USA.

Kari Russell (K)

Essentia Health, Duluth, Minnesota, USA.

Melissa Pappas (M)

Essentia Health, Duluth, Minnesota, USA.

Jessica Kiefer (J)

Essentia Health, Duluth, Minnesota, USA.

Wesley Bickler (W)

Essentia Health, Duluth, Minnesota, USA.

Anthony Wiseman (A)

Essentia Health, Duluth, Minnesota, USA.

Joel Jurantee (J)

Essentia Health, Duluth, Minnesota, USA.

R Ross Reichard (RR)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Kirk E Smith (KE)

Minnesota Department of Health, St. Paul, Minnesota, USA.

Ruth Lynfield (R)

Minnesota Department of Health, St. Paul, Minnesota, USA.

Joni Scheftel (J)

Minnesota Department of Health, St. Paul, Minnesota, USA.

Ryan M Wallace (RM)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jesse Bonwitt (J)

Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH